Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies [Phase 1, Phase 2]
Acalabrutinib is being evaluated in Phase 1/2 studies in Chinese adults with relapsed or refractory mantle cell lymphoma and chronic lymphoc…
-
CLINICAL_TRIALS trial_result · 2025-03-17Clinical Trial Update: Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia [Phase 3]
A Phase 3 study evaluating acalabrutinib in patients with chronic lymphocytic leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]
Phase 3 trial comparing pirtobrutinib (LOXO-305) against investigator's choice (idelalisib plus rituximab or bendamustine plus rituximab) in…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning with fludarabine and melphalan plus total body irradiation for haploidentical stem c…
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL [Phase 2]
Phase 2 trial evaluating the AU2 combination (acalabrutinib, umbralisib, and ublituximab) in relapsed and untreated chronic lymphocytic leuk…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide [Phase 2]
A Phase 2 trial evaluating the incidence of hepatitis B in HBsAg-positive patients with diffuse large B-cell lymphoma or chronic lymphocytic…
-
CLINICAL_TRIALS trial_result · 2025-02-20Clinical Trial Update: Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers [Phase 1]
This is a completed Phase 1 safety study of navitoclax (ABT-263) in combination with rituximab for CD20-positive lymphoid malignancies, incl…
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia Patients [EARLY_Phase 1]
A Phase 1 EARLY study is evaluating the effects of a strength-based physical exercise program in patients with chronic lymphocytic leukemia;…
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL [Phase 1]
Phase 1 study update for ONO-7018 in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia, assessing safety, tolerabili…
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies [Phase 1, Phase 2]
This completed Phase 1/2 trial evaluates the combination of cirmtuzumab and ibrutinib in patients with B-cell lymphoid malignancies, includi…
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction [Phase 1]
Phase 1 clinical trial update of romidepsin for patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction…
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL [Phase 1]
This is a Phase 1 clinical trial evaluating the combination of pembrolizumab with TGR-1202 (umbralisib) in relapsed/refractory chronic lymph…
-
CLINICAL_TRIALS trial_result · 2025-02-04Clinical Trial Update: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies [Phase 1]
Phase 1 VENOM trial evaluating venetoclax with obinutuzumab and magrolimab in relapsed and refractory indolent B-cell malignancies has compl…
-
CLINICAL_TRIALS trial_result · 2025-01-30Clinical Trial Update: Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia [Phase 3]
A Phase 3 study comparing acalabrutinib to chlorambucil plus rituximab in adults with previously untreated chronic lymphocytic leukemia has …
-
CLINICAL_TRIALS trial_result · 2025-01-29Clinical Trial Update: Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial update reporting on the combination of Ofatumumab and Ibrutinib with allogeneic bone marrow transplant or consolidation in hig…
-
CLINICAL_TRIALS trial_result · 2025-01-27Clinical Trial Update: Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML [Phase 1]
The Phase 1 trial of LAVA-051 in relapsed/refractory Chronic Lymphocytic Leukemia, Multiple Myeloma, or Acute Myeloid Leukemia has been term…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
A completed clinical trial investigated the role of large extracellular vesicles as biomarkers in various lymphomas and lymphoproliferative …
-
CLINICAL_TRIALS trial_result · 2025-01-16Clinical Trial Update: Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) [Phase 2]
Phase 2 trial evaluating acalabrutinib in patients with chronic lymphocytic leukemia and mantle cell lymphoma after allogeneic stem cell tra…
-
CLINICAL_TRIALS trial_result · 2025-01-16Clinical Trial Update: Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 trial evaluating frontline ibrutinib plus rituximab in unfit chronic lymphocytic leukemia has completed, assessing activity and sa…
-
CLINICAL_TRIALS trial_result · 2025-01-08Clinical Trial Update: Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas [Phase 2]
A Phase 2 study evaluating the triple combination therapy DTRM-555 in relapsed/refractory chronic lymphocytic leukemia and relapsed/refracto…
-
CLINICAL_TRIALS trial_result · 2024-12-31Clinical Trial Update: FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia [Phase 3]
A Phase 3 trial comparing FCR (fludarabine, cyclophosphamide, rituximab) versus BR (bendamustine, rituximab) in patients with previously unt…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression [Phase 3]
A Phase 3 trial evaluating ibrutinib in previously untreated Binet stage A chronic lymphocytic leukemia at risk of progression has been comp…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL [Phase 2]
Phase 2 trial evaluating sequential bendamustine debulking followed by obinutuzumab, acalabrutinib, and venetoclax in relapsed/refractory ch…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation [Phase 3]
A Phase 3 trial in previously untreated chronic lymphocytic leukemia without del(17p) or TP53 mutation compares standard chemoimmunotherapy …
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors [Phase 1, Phase 2]
An update on the Phase 1/2 study of CYT-0851 in B-cell malignancies and advanced solid tumors, noting completion of Phase 1/2 cohorts.